Ooops... Error 404

Sorry, but the page you are looking for doesn't exist.

Go to the homepage

Big Picture Bio founded to work on promising cancer combination therapies

biotech Jim Cornall -
Big Picture Bio Ltd., has been founded to identify, design and optimise promising cancer combination therapies, using a generative world model to understand how...

Earlier asthma diagnosis could bring relief

biotech Jim Cornall -
Blowing into a tube to diagnose asthma is not easy for babies or toddlers. Babies and young children suspected of having asthma therefore inevitably remain...

Stem cells can contribute to new treatments for heart attacks and Parkinson’s

biotech Jim Cornall -
Cells from nine “super donors” are being collected in Oslo. The aim is for these to be used to repair or replace damaged cells,...

FDA okays IND application for familial adenomatous polyposis drug

biotech Jim Cornall -
Sapience Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted the company an Investigational New Drug (IND) application for...

NTDpedia launched to fight neglected tropical diseases

biotech Jim Cornall -
The Global Health Innovative Technology (GHIT) Fund has launched NTDpedia: Your Guide to Neglected Tropical Diseases. Designed as an accessible, visually intuitive digital encyclopaedia, NTDpedia...

Base to Base biotech podcast 76: Early disease detection and beating CNS cancers

biotech Jim Cornall -
This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun...

‘Positive trends’ from phase 2 amyotrophic lateral sclerosis trial

biotech Jim Cornall -
Axoltis Pharma has announced topline results of SEALS, its phase 2 clinical trial evaluating the effect of NX210c in patients with amyotrophic lateral sclerosis...

Successful results from trial of first-in-class Parkinson’s disease peptide

biotech Jim Cornall -
Teitur Trophics, a biotechnology company developing novel neuroprotective peptides for neurodegenerative diseases, has announced successful results from its phase I clinical trial of its...
- Advertisement -spot_img

Latest Articles

Load more